Intra-Cellular Therapies Inc reports results for the quarter ended in March - Earnings Summary

Intra-Cellular Therapies

10/05/2022 15:20

* Intra-Cellular Therapies Inc  ITCI.OQ  reported a
quarterly
adjusted loss of 78 cents​​ per share for the quarter ended in
March. The mean expectation of eleven analysts for the quarter
was for a loss of 92 cents per share.
    * Revenue rose 120.4% to $35.00 million from a year ago; 
analysts
expected $33.65 million. 
    * Intra-Cellular Therapies Inc's reported EPS for the
quarter was
a loss of 78 cents​.
    * The mean earnings estimate of analysts had fallen by
about 11.7%
in the last three months.​ 
    * In the last 30 days one analyst negatively revised an
earnings
estimate 
    * Intra-Cellular Therapies Inc shares had fallen by 29.7%
this
quarter and lost 17.8% so far this year.
    * The company reported a quarterly loss of $72.12 million.
    * Wall Street's median 12-month price target for
Intra-Cellular
Therapies Inc is $70.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 11 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 

This summary was machine generated May 10 at 02:20 p.m.  ​All
figures in US dollars unless otherwise stated